MedTrace Logo

Maintenance Therapy With Subcutaneous Bortezomib

NCT01913730 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 63

Last updated 2023-12-13

No results posted yet for this study

Summary

This is a multicenter, randomized, open label study designed to evaluate the efficacy and safety of prolonged treatment with bortezomib twice monthly and dexamethasone after a salvage treatment containing bortezomib for relapsed or refractory multiple myeloma patients.

Conditions

Interventions

DRUG

Bortezomib

DRUG

Dexamethasone

Sponsors & Collaborators

  • Fondazione EMN Italy Onlus

    collaborator OTHER

  • European Myeloma Network B.V.

    lead NETWORK

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-11-30
Primary Completion
2021-04-30
Completion
2023-09-07

Countries

  • Italy

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01913730 on ClinicalTrials.gov